See more : VersaBank (VBNK.TO) Income Statement Analysis – Financial Results
Complete financial analysis of NLS Pharmaceutics AG (NLSP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NLS Pharmaceutics AG, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mingxin Automotive Leather Co., Ltd. (605068.SS) Income Statement Analysis – Financial Results
- Hunan Zhenghong Science and Technology Develop Co.,Ltd. (000702.SZ) Income Statement Analysis – Financial Results
- Satori Resources Inc. (BUD.V) Income Statement Analysis – Financial Results
- NexPoint Residential Trust, Inc. (NXRT) Income Statement Analysis – Financial Results
- Bite Acquisition Corp. (BITE-UN) Income Statement Analysis – Financial Results
NLS Pharmaceutics AG (NLSP)
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 11.41K | 11.41K | 10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -11.41K | -11.41K | -10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.91M | 8.98M | 5.92M | 99.58K | 1.70M | 1.44M | 4.32M |
| General & Administrative | 5.90M | 6.51K | 5.94K | 2.20K | 3.30M | 2.01M | 1.44M |
| Selling & Marketing | 0.00 | 6.49M | 5.93M | 2.20M | 2.49M | 0.00 | 0.00 |
| SG&A | 5.90M | 6.49M | 5.93M | 2.20M | 2.49M | 2.01M | 1.44M |
| Other Expenses | 0.00 | 10.05K | -17.32K | -328.37K | 0.00 | -629.23K | 0.00 |
| Operating Expenses | 11.81M | 15.47M | 11.85M | 2.30M | 4.20M | 3.45M | 5.77M |
| Cost & Expenses | 11.81M | 15.48M | 11.86M | 2.30M | 4.20M | 3.45M | 5.77M |
| Interest Income | 0.00 | 100.87 | 68.13 | 233.70 | 819.71 | 16.04K | 890.40 |
| Interest Expense | 145.15K | 100.87K | 68.13K | 233.70K | 819.71K | 1.07M | 890.40K |
| Depreciation & Amortization | 11.41K | 11.41K | 10.05K | 2.30M | 4.20M | 3.45M | 5.77M |
| EBITDA | -11.80M | -15.47M | -11.85M | 0.00 | -430.40K | -613.20K | -5.77M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.81M | -15.48M | -11.86M | -2.30M | -4.20M | -3.45M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -364.97K | -1.01M | -85.46K | -562.07K | -1.25M | -1.70M | -890.40K |
| Income Before Tax | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.00 | -226.51K | -2.30K | -4.20K | 1.70M | -5.77K |
| Net Income | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| EPS Diluted | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| Weighted Avg Shares Out | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
| Weighted Avg Shares Out (Dil) | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market
ZURICH , Dec. 4, 2024 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
ZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd.
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence
ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is pleased to announce that its...
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
ZURICH, SWITZERLAND / ACCESSWIRE / October 15, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
ZURICH, SWITZERLAND / ACCESSWIRE / September 25, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday.
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
NLS Pharmaceutics (NASDAQ: NLSP ) stock is on the rise Monday after the clinical-stage biopharmaceutical company announced a merger agreement with Kadimastem. This agreement will see Kadimastem acquired by a wholly-owned subsidiary of NLS Pharmaceutics.
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support for the...
Source: https://incomestatements.info
Category: Stock Reports